vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and FIRST INTERSTATE BANCSYSTEM INC (FIBK). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $313.0M, roughly 1.3× FIRST INTERSTATE BANCSYSTEM INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 34.8%, a 25.7% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 19.8%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 13.7%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

First Interstate BancSystem, Inc. is a financial holding company headquartered in Billings, Montana. It is the parent company of First Interstate Bank, a community bank with locations throughout 14 states within the Western and Midwestern United States. It is the largest bank based in Montana, as measured by total assets.

BCRX vs FIBK — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.3× larger
BCRX
$406.6M
$313.0M
FIBK
Growing faster (revenue YoY)
BCRX
BCRX
+189.3% gap
BCRX
209.1%
19.8%
FIBK
Higher net margin
BCRX
BCRX
25.7% more per $
BCRX
60.5%
34.8%
FIBK
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
13.7%
FIBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCRX
BCRX
FIBK
FIBK
Revenue
$406.6M
$313.0M
Net Profit
$245.8M
$108.8M
Gross Margin
97.7%
Operating Margin
64.0%
44.5%
Net Margin
60.5%
34.8%
Revenue YoY
209.1%
19.8%
Net Profit YoY
1017.5%
108.8%
EPS (diluted)
$1.13
$1.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
FIBK
FIBK
Q4 25
$406.6M
$313.0M
Q3 25
$159.4M
$250.5M
Q2 25
$163.4M
$248.3M
Q1 25
$145.5M
$247.0M
Q4 24
$131.5M
$261.3M
Q3 24
$117.1M
$251.9M
Q2 24
$109.3M
$244.3M
Q1 24
$92.8M
$242.2M
Net Profit
BCRX
BCRX
FIBK
FIBK
Q4 25
$245.8M
$108.8M
Q3 25
$12.9M
$71.4M
Q2 25
$5.1M
$71.7M
Q1 25
$32.0K
$50.2M
Q4 24
$-26.8M
$52.1M
Q3 24
$-14.0M
$55.5M
Q2 24
$-12.7M
$60.0M
Q1 24
$-35.4M
$58.4M
Gross Margin
BCRX
BCRX
FIBK
FIBK
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
BCRX
BCRX
FIBK
FIBK
Q4 25
64.0%
44.5%
Q3 25
18.6%
37.0%
Q2 25
18.2%
37.7%
Q1 25
14.6%
26.9%
Q4 24
-3.4%
25.5%
Q3 24
6.6%
28.9%
Q2 24
8.0%
32.1%
Q1 24
-15.6%
31.7%
Net Margin
BCRX
BCRX
FIBK
FIBK
Q4 25
60.5%
34.8%
Q3 25
8.1%
28.5%
Q2 25
3.1%
28.9%
Q1 25
0.0%
20.3%
Q4 24
-20.4%
19.9%
Q3 24
-12.0%
22.0%
Q2 24
-11.6%
24.6%
Q1 24
-38.1%
24.1%
EPS (diluted)
BCRX
BCRX
FIBK
FIBK
Q4 25
$1.13
$1.07
Q3 25
$0.06
$0.69
Q2 25
$0.02
$0.69
Q1 25
$0.00
$0.49
Q4 24
$-0.13
$0.50
Q3 24
$-0.07
$0.54
Q2 24
$-0.06
$0.58
Q1 24
$-0.17
$0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
FIBK
FIBK
Cash + ST InvestmentsLiquidity on hand
$274.7M
Total DebtLower is stronger
$146.3M
Stockholders' EquityBook value
$-119.2M
$3.4B
Total Assets
$514.2M
$26.6B
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
FIBK
FIBK
Q4 25
$274.7M
Q3 25
$212.9M
Q2 25
$260.0M
Q1 25
$295.1M
Q4 24
$320.9M
Q3 24
$96.8M
Q2 24
$78.4M
Q1 24
$84.3M
Total Debt
BCRX
BCRX
FIBK
FIBK
Q4 25
$146.3M
Q3 25
$146.2M
Q2 25
$252.0M
Q1 25
Q4 24
$132.2M
Q3 24
$137.3M
Q2 24
$383.4M
Q1 24
$370.8M
Stockholders' Equity
BCRX
BCRX
FIBK
FIBK
Q4 25
$-119.2M
$3.4B
Q3 25
$-387.9M
$3.4B
Q2 25
$-421.6M
$3.4B
Q1 25
$-451.9M
$3.4B
Q4 24
$-475.9M
$3.3B
Q3 24
$-468.6M
$3.4B
Q2 24
$-475.6M
$3.2B
Q1 24
$-476.2M
$3.2B
Total Assets
BCRX
BCRX
FIBK
FIBK
Q4 25
$514.2M
$26.6B
Q3 25
$446.4M
$27.3B
Q2 25
$457.2M
$27.6B
Q1 25
$480.0M
$28.3B
Q4 24
$490.4M
$29.1B
Q3 24
$491.3M
$29.6B
Q2 24
$472.4M
$30.3B
Q1 24
$467.9M
$30.1B
Debt / Equity
BCRX
BCRX
FIBK
FIBK
Q4 25
0.04×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
Q4 24
0.04×
Q3 24
0.04×
Q2 24
0.12×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
FIBK
FIBK
Operating Cash FlowLast quarter
$292.0M
$305.6M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
2.81×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
FIBK
FIBK
Q4 25
$292.0M
$305.6M
Q3 25
$41.6M
$91.7M
Q2 25
$41.3M
$68.1M
Q1 25
$-27.5M
$78.5M
Q4 24
$-5.2M
$355.0M
Q3 24
$8.2M
$89.9M
Q2 24
$-1.4M
$82.3M
Q1 24
$-53.7M
$87.6M
Free Cash Flow
BCRX
BCRX
FIBK
FIBK
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
Q1 24
$-53.9M
FCF Margin
BCRX
BCRX
FIBK
FIBK
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Q1 24
-58.1%
Capex Intensity
BCRX
BCRX
FIBK
FIBK
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
BCRX
BCRX
FIBK
FIBK
Q4 25
1.19×
2.81×
Q3 25
3.23×
1.28×
Q2 25
8.12×
0.95×
Q1 25
-859.91×
1.56×
Q4 24
6.81×
Q3 24
1.62×
Q2 24
1.37×
Q1 24
1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons